Evidence map›Paper›PMID 33863821›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022

Direct Comparison of the Tau PET Tracers

Alexandra Gogola, Davneet S Minhas, Victor L Villemagne, Ann D Cohen, James M Mountz, Tharick A Pascoal, Charles M Laymon, N Scott Mason, Milos D Ikonomovic, Chester A Mathis and 4 more

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 1 synthesis or guideline pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. [European journal of nuclear medicine and molecular imaging · 2026
    Article
  4. Article
  5. Article
  6. ATNIVS biomarker heterogeneity in real-world patients receiving lecanemab.The journal of prevention of Alzheimer's disease · 2026
    Article
  7. Article
  8. Review
  9. Off-target binding ofAnnals of nuclear medicine · 2026
    Article
  10. Elevated AD biomarkers do not explain cognitive performance in a community-recruited clinical trial cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  11. Associations ofAlzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  12. Evaluation of [Acta neuropathologica communications · 2026
    Article
  13. Article
  14. Article
  15. Tau in Alzheimer's disease: Shaping the future patient journey.The journal of prevention of Alzheimer's disease · 2026
    Review
  16. Review
  17. Evaluation of [Research square · 2026
    Article
  18. Review
  19. Article
  20. Mesial temporal tau pathology impacts basal forebrain degeneration in early Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Alexandra GogolaDepartment of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Davneet S MinhasDepartment of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Victor L VillemagneDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.
Ann D CohenDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.
James M MountzDepartment of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Tharick A PascoalDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.
Charles M LaymonDepartment of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania.
N Scott MasonDepartment of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Milos D IkonomovicDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.
Chester A MathisDepartment of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Beth E SnitzDepartment of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Oscar L LopezDepartment of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania.
William E KlunkDepartment of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania.
Brian J LoprestiDepartment of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania; brianl@pitt.edu.
University of Pittsburgh · US

Funding

TREATMENT OF DEPRESSION IN ALZHEIMER'S DISEASEP50AG005133 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KAMBOH, M. ILYAS · 1985 to 2019
$43.0M
Research Education ComponentP30AG066468 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI C. Elizabeth Shaaban · 2020 to 2026
$29.4M
NIA NIH HHS P30 AG066468NIA NIH HHS P50 AG005133
6 · The paper itself

Abstract

Tau PET tracers exhibit varying levels of specific signal and distinct off-target binding patterns that are more diverse than amyloid PET tracers. This study compared 2 frequently used tau PET tracers,

Indexed as

CarbolinesPositron-Emission Tomographytau ProteinsAgedAged, 80 and overAlzheimer DiseaseBrainFemaleFluorine RadioisotopesHumansIsoquinolinesMaleMiddle AgedRadiopharmaceuticals7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indoleCarbolinesFluorine RadioisotopesIsoquinolinesMK-6240Radiopharmaceuticalstau Proteins18F-flortaucipir18F-MK-6240Alzheimer diseasePETtau

Identifiers

PMID33863821
PMCPMC8717175
OpenAlexW3153452326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.